Peptide antiandrogen
So-called peptide antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer. In spite of the title, peptide antiandrogens are not actually peptides. Examples of peptide antiandrogens include EPI-001, EPI-506, and BAY-1024767.[1]
See also
References
- ↑ Monaghan, AmyE; McEwan, IainJ (2016). "A sting in the tail: the N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology. 0 (0): 0. doi:10.4103/1008-682X.181081. ISSN 1008-682X.
| AR |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GPRC6A |
| ||||||||||
See also: Estrogenics • Glucocorticoidics • Mineralocorticoidics • Progestogenics • Steroid hormone metabolism modulators • List of androgens/anabolic steroids | |||||||||||
This article is issued from Wikipedia - version of the 6/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.